Esophageal string test to screen for eosinophilic esophagitis in adults of African descent with swallowing problems
Official title: Use of the Esophageal String Test as a Diagnostic Screening Tool for Eosinophilic Esophagitis Among Africans With Dysphagia in Mali and the United States
Run by National Institutes of Health Clinical Center (CC) · NCT07027826 · Data updated 2026-11-12
This study will test whether a 1-hour esophageal string test can detect eosinophilic esophagitis in adults born in Africa (or with African parents) who have trouble swallowing.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 65 Years |
| Sex | All |
| Enrollment | 70 (estimated) |
| Sponsor | National Institutes of Health Clinical Center (CC) NIH |
| Drugs / interventions | dupilumab, mepolizumab, reslizumab, benralizumab, cendakimab, tezepelumab, barzolvolimab |
| Locations | 3 sites (Bethesda, Maryland and 2 other locations) |
| Status | Recruiting |
| Started | November 15, 2026 |
| Main results expected | August 31, 2027 |
| Study ends | August 31, 2027 |
| Registry record updated | November 10, 2026 |
| Trial ID | NCT07027826 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults 18–65 with dysphagia or prior food impaction who were born in Africa or have parents born in Africa and who are willing to undergo the EST and a clinically indicated endoscopy.
✕Probably not a fit
People outside the 18–65 age range, without African birth or parentage, without swallowing symptoms, or who recently used systemic or topical steroids or certain biologic drugs are unlikely to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The study enrolls adults aged 18–65 who were born in Africa or have parents born in Africa and who have symptoms of dysphagia and are scheduled for clinically indicated upper endoscopy in Mali or the United States. Each participant will undergo a 1-hour esophageal string test (EST) immediately prior to esophagogastroduodenoscopy, with biopsy results serving as the reference standard. Investigators will collect blood, urine, stool, skin swabs, environmental air and water samples, and standardized symptom and exposure questionnaires to explore biomarkers and potential environmental contributors. The main aim is to compare EST findings with biopsy results to estimate the EST’s accuracy for identifying eosinophilic esophagitis in this population.
Why it matters
Potential benefit: If successful, the EST could offer a faster, cheaper, and less invasive way to screen for eosinophilic esophagitis and reduce reliance on diagnostic endoscopy.
How similar studies have gone: Previous studies have shown the EST can detect eosinophilic esophagitis in other populations, but its performance among people of African descent and in community settings remains less well established.
Who can join: the full rules
Show full inclusion / exclusion criteria
* INCLUSION CRITERIA: In order to be eligible to participate in this study, an individual must meet all of the following criteria: 1. Able to provide informed consent. 2. Aged 18 to 65 years. 3. Born in the African continent or their parents were born in Africa, 4. Exhibiting symptoms of dysphagia and/or prior history of food impaction. 5. Undergoing clinically indicated endoscopy at the NIH Clinical Center (U.S.), Centre Hospitalier Universitaire Gabriel Tour(SqrRoot)(Copyright) (Mali), or other local clinics (Mali) and willing to provide research samples and data. EXCLUSION CRITERIA: An individual who meets any of the following criteria will be excluded from participation in this study: 1. Recent steroid use (systemic or swallowed/topical corticosteroid) within 4 weeks prior to endoscopy. 2. Recent use of dupilumab (Dupixent) within the last 6 months. 3. Recent use of other biologic medications (within either 6 months or 5 half-lives, whichever is longer). Examples of biologic medications include: 3a. mepolizumab (Nucala) 3b. reslizumab (Cinqair, Cinqaero) 3c. benralizumab (Fasenra) 3d. cendakimab 3e. tezepelumab (Tezspire) 3f. barzolvolimab 4\. Individuals suffering from a bleeding diathesis (e.g., hemophilia, severe thrombocytopenia). 5\. Current use of anticoagulant medications. 6\. Pregnancy. 7\. Treatment with another investigational drug or other investigational intervention within 6 months or 5 half-lives whichever is longer. 8\. Individuals with a known history of any of the following: 8a. eosinophilic esophagitis 8b. esophageal stricture unable to be passed with an upper endoscope 8c. esophageal cancer 8d. esophageal motility disorder (e.g., achalasia) 8e. esophageal varices 8f. esophageal or gastric surgery including fundoplication 8g. neurologic cause of dysphagia (e.g., stroke, Parkinson s disease, etc.) 8h. allergy to gelatin 8i. inability to swallow pills 9\. Any condition that, in the investigator s opinion, places the individual at undue risk by participating in the study. Co-enrollment guidelines: Co-enrollment in other trials is restricted, other than enrollment on observational studies. Consideration for co-enrollment in trials evaluating the use of a licensed medication will require the approval of the principal investigator in consultation with the medical monitor. Study staff should be notified of co-enrollment on any other protocol as it may require the approval of the principal investigator.
Where it's running
-
National Institutes of Health Clinical Center
Bethesda, Maryland, United States Recruiting -
Gabriel Toure University Hospital Center
Bamako, Mali Not yet recruiting -
Mali International Center for Excellence in Research
Bamako, Mali Not yet recruiting
Study contacts
- Principal investigator: Gregory M Constantine, M.D. — National Institute of Allergy and Infectious Diseases (NIAID)
- Study coordinator: Gregory M Constantine, M.D.
- Email: constantinegm@nih.gov
- Phone: (301) 633-6453
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
How surgery for obstructive sleep apnea affects swallowing and oral function
This study compares swallowing and oral function before and after surgical treatment for OSA versus non-surgical care in adults with moderate-to-severe OSA.
-
taVNS added to oral motor training for babies with severe swallowing trouble
This trial tests whether pairing a noninvasive taVNS treatment with oral sensorimotor training helps infants in NICUs swallow better and feed more safely.
-
Digital Tongue-Pressure Biofeedback Training for Post-Stroke Swallowing
This study tests whether digital tongue-pressure biofeedback training helps people with swallowing difficulties after stroke.
-
Masseter and Thigh Muscle Ultrasound to Predict Dysphagia and Sarcopenia in Critically Ill Adults
This study tests whether measuring the masseter muscle with ultrasound can help identify dysphagia in adults after critical illness and extubation, alongside evaluation of sarcopenia.
-
Impact of Patient Position on EndoFLIP Measurements in Kids and Young Adults
This study tests whether EndoFLIP measurements differ when patients are in the supine versus left-side position during the procedure.
-
Effects of CTAR and a Swallowing Pressure Ball in Older Stroke Adults
This study tests whether home-based CTAR exercises plus a swallowing pressure ball can improve swallowing function and eating-related quality of life for older adults who had a stroke and have dysphagia.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.